IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+3.95%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$672M
AUM Growth
+$672M
(+23%)
Cap. Flow
+$83.3M
Cap. Flow
% of AUM
12.4%
Top 10 Holdings %
Top 10 Hldgs %
24.63%
Holding
266
New
64
Increased
37
Reduced
43
Closed
20
Top Buys
| 1 |
Eli Lilly
LLY
|
$23.4M |
| 2 |
MacroGenics
MGNX
|
$15.9M |
| 3 |
Galapagos
GLPG
|
$15.5M |
| 4 |
X4 Pharmaceuticals
XFOR
|
$15.4M |
| 5 |
Relmada Therapeutics
RLMD
|
$10.2M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$29.5M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$19.7M |
| 3 |
Prothena Corp
PRTA
|
$18.8M |
| 4 |
Bristol-Myers Squibb
BMY
|
$17.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$15.8M |
Sector Composition
| 1 | Healthcare | 98.54% |
| 2 | Consumer Staples | 0.23% |
| 3 | Financials | 0.12% |
| 4 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $23.4M | 0.79% | +125,000 | New | +$23.4M |
|
|
2
X4 Pharmaceuticals
XFOR
$84.2M
| $22.5M | 0.76% | 2,614,988 +1,788,564 | +216% | +$15.4M |
|
|
TCON
3
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $22.4M | 0.75% | 2,716,840 | – | – |
|
|
4
MacroGenics
MGNX
$112M
| $15.9M | 0.54% | +500,469 | New | +$15.9M |
|
|
5
Galapagos
GLPG
$2.07B
| $15.5M | 0.52% | +200,000 | New | +$15.5M |
|
|
CMRX
6
DELISTED
Chimerix, Inc.
CMRX
| $15.4M | 0.52% | 1,597,514 +365,001 | +30% | +$3.52M |
|
7
Curis
CRIS
$20.9M
| $13.8M | 0.47% | 1,220,356 -354,644 | -23% | -$4.01M |
|
|
8
Celldex Therapeutics
CLDX
$1.47B
| $12.3M | 0.41% | 596,290 -768,700 | -56% | -$15.8M |
|
|
TVRD
9
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $12.1M | 0.41% | 558,524 +285,000 | +104% | +$6.19M |
|
|
IMAB
10
I-MAB
IMAB
$340M
| $12.1M | 0.41% | 250,000 +100,000 | +67% | +$4.85M |
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $11.5M | 0.39% | 640,576 +417,403 | +187% | +$7.47M |
|
|
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.2M | 0.38% | 330,989 +50,000 | +18% | +$1.7M |
|
|
13
Prothena Corp
PRTA
$441M
| $11M | 0.37% | 437,430 -749,270 | -63% | -$18.8M |
|
14
Milestone Pharmaceuticals
MIST
$156M
| $10.6M | 0.36% | 1,836,545 | – | – |
|
15
Protara Therapeutics
TARA
$120M
| $10.2M | 0.34% | 649,542 | – | – |
|
|
16
Relmada Therapeutics
RLMD
$37.2M
| $10.2M | 0.34% | +290,207 | New | +$10.2M |
|
17
Vaxcyte
PCVX
$4B
| $9.9M | 0.33% | 501,110 +225,000 | +81% | +$4.44M |
|
18
Gossamer Bio
GOSS
$562M
| $9.7M | 0.33% | 1,048,383 | – | – |
|
19
Disc Medicine
IRON
$2.07B
| $9.27M | 0.31% | +684,379 | New | +$9.27M |
|
20
Lyra Therapeutics
LYRA
$11.5M
| $9.05M | 0.3% | 780,728 -34,636 | -4% | -$401K |
|
21
scPharmaceuticals
SCPH
$295M
| $8.7M | 0.29% | 1,308,699 -157,448 | -11% | -$1.05M |
|
|
VINC
22
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $8.47M | 0.29% | 438,684 -100,000 | -19% | -$1.93M |
|
|
CMPS
23
Compass Pathways
CMPS
$424M
| $8.32M | 0.28% | 225,926 +202,278 | +855% | +$7.45M |
|
24
Ascendis Pharma
ASND
$11.8B
| $8M | 0.27% | 62,090 -25,000 | -29% | -$3.22M |
|
25
ESSA Pharma
EPIX
$11.4M
| $7.69M | 0.26% | +264,868 | New | +$7.69M |
|